N. C. Karpilovsky, T. Goiran, K. Senkevich, G. Deyab, N. Twells, E. N. Cha, E. J. MacDougall, Z. Wang, J. Sirois, G. Macleod, L. Liu, M. Ghamgosar Shahkhali, K. Ali Boubacar, J. Jones-Tabah, I. Pietrantonio, W. Luo, I. Shlaifer, E. Del Cid-Pellitero, A. Kulepa, E. B. Affar, S. Angers, J. Liu, L. K. Mahal, T. M. Durcan, Z. Gan-Or, E. A. Fon
A central hallmark of Parkinson's disease (PD) is the spread of -Synuclein (-Syn) aggregates, which is thought to contribute to its progressive nature. To better understand the mechanism of cellular internalization of -Syn fibrils, we conducted a genome wide CRISPR activation (CRISPRa) screen to identify genetic modifiers of fibril uptake. We report here BRCA associated protein 1 (BAP1) as a regulator of fibril uptake into cells and validate its association with the genetic risk of PD. BAP1 regulates fibril entry into cells by acting as a master transcriptional regulator of the cell surface glycoproteome. BAP1 downregulates Heparan Sulfate Proteoglycan (HSPG) and upregulates O-linked glycoprotein expression, the net effect of which is to reduce fibril internalization. The effect of enhancing BAP1 expression is cell-type specific, as it reduces Syn uptake in iPSC-derived dopaminergic neurons, but not in microglia. Using human midbrain organoids with integrated microglia, we find this effect is mediated through ASXL3 another PD risk gene and a non-obligatory component of the BAP1 Polycomb Repressive-Deubiquitinase Complex (PR-DUB). These findings are consistent with higher BAP1/ASXL3 co-expression in regions of the brain less vulnerable to PD pathology. Together, the work uncovers a novel role for BAP1/ASXL3 in regulating Syn fibril internalization by remodelling the cell surface glycoproteome.